我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

益气养阴固本法治疗晚期非小细胞肺癌疗效观察(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2017年06期
页码:
30-32,36
栏目:
临床研究
出版日期:
2018-03-19

文章信息/Info

Title:
-
作者:
徐晓敏1温桂兰2沈治祥3熊燕1顾芬4
1. 上海市普陀区人民医院中医科,上海 200060;2. 上海市嘉定区中医医院妇产科,上海 201800;3. 上海市嘉定区中医医院外科,上海 201800;4. 同济大学附属上海市肺科医院肿瘤科,上海 200433
Author(s):
-
关键词:
益气养阴固本 吉西他滨 奈达铂 非小细胞肺癌
Keywords:
-
分类号:
R273
DOI:
10.19288/j.cnki.issn.1000-2723.2017.06.008
文献标识码:
A
摘要:
目的 观察益气养阴固本法联合吉西他滨(Gemcitabine,GEM)、奈达铂(Nedaplatin,NDP)化疗方案对晚期非小细胞肺癌(Non-Small Cell Lung Cancer,NSCLC)疗效。方法 选择2014年8月—2016年8月在我院接受化疗的晚期NSCLC患者68例,随机分为观察组(n=34)和对照组(n=34)。对照组接受GEM联合NDP化疗方案进行治疗,观察组在此化疗方案的基础上给予益气养阴固本法进行治疗。对2组患者近期疗效进行评价对比;统计2组治疗前后生活质量是卡氏评分法(Karnofsky,KPS)评分及免疫功能变化。结果 ①观察组缓解率为47.1%(16/34),对照组缓解率为26.5%(9/34),2组缓解率相比,差异具有统计学意义(P<0.05);②治疗前2组患者的KPS评分差异不显著(P>0.05),治疗后,观察组KPS评分为76.3±9.1分,明显高于对照组患者KPS评分为63.6±8.6分,组间比较差异有统计学意义(P<0.05);③治疗前2组CD3+、CD4+、CD4+/CD8+和NK细胞活性无差异(P>0.05),治疗后观察组CD3+、CD4+、CD4+/CD8+和NK细胞活性(分别为67.2±5.2、38.8±5.1、1.4±0.4、36.2±2.7)均明显高于对照组(分别为63.7±4.6、30.6±4.8、1.0±0.2、32.2±3.1),组间比较差异有统计学意义(P<0.05)。结论 益气养阴固本法联合GEM、NDP化疗方案在晚期NSCLC治疗中可提高临床疗效。
Abstract:
-

参考文献/References

[1] Kimura T,Taniguchi H,Watanabe N,et al. Phase II study of carboplatin and pemetrexed in advanced EGFR-wild-type non-squamous non-small cell lung cancer:the central Japan lung study group trial 0906[J]. Anticancer Research,2016,36(4):1767-1771.
[2] De GJ,Van MJ,Vansteenkiste JF,et al. Prospective evaluation of first-line erlotinib in advanced non-Small cell lung cancer(NSCLC)carrying an activating EGFR mutation:a multicenter academic phase II study in caucasian patients(FIELT)[J]. PloS One,2016,11(3):e0147599.
[3] 吴晓东,唐良法,江莲,等. 西妥昔单抗联合NP方案治疗晚期非小细胞肺癌疗效观察[J]. 临床肺科杂志,2012,17(10):1920-1921.
[4] Kendra K L,Plummer R,Salgia R,et al. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors[J]. Mol Cancer Ther,2015,14(2):461-469.
[5] 王根和,吴鹏飞,方平,等. 单中心单臂Ⅱ期临床研究:沙利度胺治疗一代TKI继发性耐药的晚期非小细胞肺癌的临床疗效及安全性[J]. 肿瘤药学,2016,6(3):193-197.
[6] Fasano M,Della Corte CM,Capuano A,et al. A multicenter,open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients:treatment rationale and protocol dynamics of the METAL trial[J]. Clinical Lung Cancer,2015,16(1):57-59.
[7] Chen M,May BH,Zhou IW,et al. Meta-Analysis of Oxaliplatin-Based Chemotherapy Combined With Traditional Medicines for Colorectal Cancer:Contributions of Specific Plants to Tumor Response[J]. Integr Cancer Ther,2016,15(1):40-59.
[8] Kessler ER,Eckhardt SG,Pitts TM,et al. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers[J]. Invest New Drugs,2016,34(2):176-183.
[9] Sakata S,Sasaki J,Saeki S,et al. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer:Kumamoto thoracic oncology study group trial 1002[J]. Oncology,2015,88(4):201-207.
[10] 史国军,施航,叶兴涛,等. 中医药联合吉非替尼治疗中晚期非小细胞肺癌随机对照试验的系统评价[J]. 中华中医药学刊,2015,29(3):700-704.
[11] Mok T,Wu YL,Lee JS,et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy[J]. Clinical Cancer Research,2015,21(2):3196-3203.
[12] 付陆军. 艾迪注射液联合GP化疗对老年晚期非小细胞肺癌的临床疗效分析[J]. 中国医药指南,2012(26):466.
[13] Takeda M,Yamanaka T,Seto T,et al. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer(West Japan Oncology Group 5910L):an open-label,randomized,phase 2 trial[J]. Cancer,2016,122(7):1050-1059.
[14] Li DP,Li W,Feng J,et al. Adjuvant chemotherapy with sequential cytokine-induced killer(CIK)cells in stage IB non-small cell lung cancer[J]. Oncology Research,2015,22(2):67-74.
[15] 姜海伟,胡晴,和单凤,等. 免疫相关疗效评价标准在中医药治疗晚期非小细胞肺癌的临床应用[J]. 中国中西医结合杂志,2015,35(9):1074-1077.

备注/Memo

备注/Memo:
* 基金项目: 上海市科技发展计划项目(YK2014124)
收稿日期: 2017 - 12- 13
作者简介: 徐晓敏(1986-),女,上海人,主管护师,研究方向:呼吸疾病的中西医护理。
△通信作者: 顾芬,E-mail:gufen927@163.com
更新日期/Last Update: 2017-12-20